Elias University Emergency Hospital — Clinical Trial Site

27 Registered trials

12 Currently recruiting

Organisation

Elias University Emergency Hospital

Location

Bucharest, Romania

Identifier

ORG-100028956

Address

Bulevardul Marasti 17, 011461, Romania

Departments

#3211: Cardiology
8610: Cardiology
ATI
Cardiologie
Cardiology
Clinic of Gastroenterology
Clinica de Oncologie
Emergency, intensive care
Gastroenterology
Gastroenterology, hepatology and digestive endoscopy
Medical Oncology
Neurology
Pneumologie si Terapie Acuta Respiratorie
Pneumology Medical Department
Secţia Clinică de Pneumologie
Sectia Clinica Gastroenterologie
Sectia Clinica Neurologie
Sectia Clinica Pneumologie
Sectia Oncologie Medicala
Sectie Clinica Neurologie

Clinical trials at this site (27)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Phase 3 trial of VMX-C001 vs usual pharmacological care in patients taking a FXa direct oral anticoagulant who require urgent surgery with o… Pending

2025-521632-12-00 Patients on Factor Xa inhibitor treatment needing an ur 5
A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative co… Pending

2025-522511-42-00 Crohn's disease 4
A study to learn if DM199 drug is safe and whether it works better than placebo for treating acute ischemic stroke Recruiting

2024-513911-28-00 Acute Ischemic Stroke 10 2026-03-04
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of Trepostini… Recruiting

2025-521558-40-00 Pulmonary Hypertension Associated with Interstitial Lun 5 2026-02-12
Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures Recruiting

2024-514499-42-00 Refractory Partial Onset Epilepsy 5 2025-03-12
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting

2023-506235-15-00 Limited-Stage Small-Cell Lung Cancer (LS SCLC) 5 2024-11-07
Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by … Recruiting

2024-516739-29-00 Relapsing-remitting multiple sclerosis 4 2019-01-23
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmona… Recruiting

2024-517457-27-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2025-06-04
A study to investigate efficacy and safety of SAR441566 in patients with Crohn's disease. Recruiting

2024-512633-32-00 Crohn's disease 4 2025-04-07
A WORLD-WIDE CLINICAL STUDY TO FIND OUT IF INTRAVENOUS RECOMBINANT HUMAN PLASMA GELSOLIN IS SAFE AND IS BENEFICIAL FOR TREATING ACUTE RESPIR… Recruiting

2023-510109-16-00 Acute Respiratory Distress Syndrome (ARDS) Due to Pneum 4 2025-01-06
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered-Dose Inhaler on Cardiopulmonary Outcomes in C… Recruiting

2023-507407-59-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2024-07-04
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
A study looking at how effective and safe AZD7798 is in people with Crohn's disease Ended

2023-510487-12-00 Crohn's Disease 4 2024-11-29
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended

2024-510735-21-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2021-11-26
ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended

2023-506926-35-00 Atherosclerotic cardiovascular disease, chronic kidney 5 2021-09-24
Trastuzumab deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab as First-line Treatment in HER2-positive… Ended

2023-505249-24-00 HER2-positive metastatic breast cancer 5 2021-05-27
Phase 2 Study of CAL02 plus Standard of Care in Severe Community-Acquired Bacterial Pneumonia (SCABP) Halted

2022-502049-91-00 SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP) 4 2023-09-26
Clinical trial of V940 and pembrolizumab in people with resectable locally advanced cutaneous squamous cell carcinoma Ended

2023-505712-37-00 The participants must have a histologically confirmed d 10 2024-06-06